The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 25, 2022

Filed:

Apr. 18, 2017
Applicants:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

The Board of Regents, the University of Texas System, Austin, TX (US);

Inventors:

Tong-Ming Fu, Ambler, PA (US);

Aimin Tang, Lansdale, PA (US);

Dai Wang, Blue Bell, PA (US);

Zhiqiang An, Pearland, TX (US);

Ningyan Zhang, Pearland, TX (US);

Sha Ha, Blue Bell, PA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/08 (2006.01); A61P 31/22 (2006.01); C07K 16/06 (2006.01); C12N 15/62 (2006.01);
U.S. Cl.
CPC ...
C07K 16/088 (2013.01); A61P 31/22 (2018.01); C07K 16/065 (2013.01); C12N 15/62 (2013.01); C07K 2317/21 (2013.01); C07K 2317/34 (2013.01); C07K 2317/51 (2013.01); C07K 2317/524 (2013.01); C07K 2317/72 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01);
Abstract

The present invention is directed to antigen binding proteins including, but not limited to, monoclonal antibodies and antigen binding fragments thereof, that specifically bind to and preferably neutralize human cytomegalovirus (CMV). The antigen binding proteins of the invention are useful as a prophylactic and/or therapeutic agent for preventing and/or treating CMV infections in a patient in need thereof. Also encompassed by the invention are pharmaceutical compositions comprising the antigen binding proteins of the invention and a pharmaceutically acceptable carrier. The invention further relates to methods of using the antigen binding proteins and pharmaceutical compositions of the invention for the prevention or treatment of CMV infection in patients in need thereof.


Find Patent Forward Citations

Loading…